The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | V | Various | |
| 2 | V04 | Diagnostic agents | |
| 3 | V04C | Other diagnostic agents | |
| 4 | V04CD | Tests for pituitary function |
| Code | Title | |
|---|---|---|
| V04CD01 | Metyrapone | |
| V04CD03 | Sermorelin | |
| V04CD04 | Corticorelin | |
| V04CD05 | Somatorelin | |
| V04CD06 |
| Active Ingredient | Description | |
|---|---|---|
| Corticorelin |
Corticorelin results in a rapid and sustained increase of plasma ACTH levels and a near parallel increase of plasma cortisol. In addition corticorelin causes a concomitant and prolonged release of the related proopiomelanocortin peptides β- and γ-lipotropins (β- and γ-LPH) and β-endorphin (β-END). |
|
| Macimorelin |
Macimorelin is an orally available peptidomimetic with growth hormone (GH) secretagogue activity similar to ghrelin. Macimorelin stimulates GH release by activating growth hormone secretagogue receptors (GHSR) present in the pituitary and hypothalamus. |
|
| Mepyrapone |
|
|
| Sermorelin |
The biologically active fragment of human growth hormone-releasing factor. It is used to diagnose or treat patients with GROWTH HORMONE deficiency. |
|
| Somatorelin |
Somatorelin is normally synthesised in the hypothalamus and stimulates the secretion of growth hormone from the pituitary gland. Somatorelin physiologically increases plasma growth hormone levels. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| GHRH Lyophilised powder for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| GHRYVELIN Granules for oral suspension | European Medicines Agency (EU) | MPI, EU: SmPC | |
| METOPIRONE Capsules | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
